Evotec has provided further updates to its “priority reset” as the CRDMO exits the gene therapy space and closes a site in Austria which would affect 40 staffers.
The German company said it will no longer offer services in gene therapy — its business arm dubbed Evotec GT — and will instead focus on its “core modalities,” according to a Wednesday press release. It expanded into gene therapy in April 2020, when it also partnered with Takeda for the pharma’s gene therapy approaches.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.